Fractional Carbon Dioxide Laser Therapy Compared to Ospemifene in the Treatment of Vaginal Atrophy in Menopause.
DOI:
https://doi.org/10.56570/jimgs.v1i1.5Keywords:
Menopausal transition, Hypoestrogenism, Vulvovaginal atrophy (VVA), Treatment options, Personalized therapyAbstract
During the menopausal transition, women often experience an array of symptoms, including vaginal dryness, itching, pain, burning, decreased sexual desire, and inadequate lubrication, which are all due to hormonal changes called hypoestrogenism. Hypoestrogenism simply means a low level of estrogen which turn leads to a constellation of symptoms including hot flashes, urinary tract infections, decreased bone density and sleep disturbances. Some women find these symptoms embarrassing not to seek help, while some take it as a natural process of aging. Although various researchers have established different treatments in the past, such as lubricants and moisturizers, newer therapies such as fractional carbon dioxide (CO2) laser therapy and a selective estrogen receptor modulator ospemifene are currently being used and yet still researched. To highlight the lack of research on this topic, our article search involving only the PubMed database yielded 175 articles initially, but after exclusion and inclusion criteria, we were left with only 32 studies directly related to our research topic. Our study included English articles, full-text articles, articles on human studies, and articles from 2005-2020. We excluded all studies prior to 2005, animal studies, pediatrics study, and only abstract study. All articles were chosen without limitation to the type of study. Our review suggests that patients often present with various symptoms and severity based on histology, mechanisms, and clinical findings. Therefore, treatment should be personalized. Our study aimed to further understand a better treatment option for vulvovaginal atrophy (VVA) in postmenopausal women, knowing that menopause is an inevitable stage of a woman's life.
References
Santoro N, Epperson CN, Mathews SB: Menopausal symptoms and their management. Endocrinol Metab Clin North Am. 2015, 44:497-515. 10.1016/j.ecl.2015.05.001
Nappi RE, Palacios S: Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. Climacteric. 2014, 17:3-9. 10.3109/13697137.2013.871696
Naumova I, Castelo-Branco C: Current treatment options for postmenopausal vaginal atrophy. Int J Womens Health. 2018, 10:387-95. 10.2147/IJWH.S158913
Arroyo C: Fractional CO2 laser treatment for vulvovaginal atrophy symptoms and vaginal rejuvenation in perimenopausal women. Int J Womens Health. 2017, 9:591-5. 10.2147/IJWH.S136857
Knight C, Logan V, Fenlon D: A systematic review of laser therapy for vulvovaginal atrophy/genitourinary syndrome of menopause in breast cancer survivors. Ecancermedicalscience. 2019, 13:988. 10.3332/ecancer.2019.988
Gaspar A, Addamo G, Brandi H: Vaginal fractional co2 laser: A minimally invasive option for vaginal rejuvenation. The. American Journal of Cosmetic Surgery. 2011, 28:156-62. 10.1177/074880681102800309
Khosla D, Kumar R, Nijhawan R, Patel F, Sharma S, Gowda K: Leiomyosarcoma of the vagina: A rare entity with comprehensive review of the literature. Int J App Basic Med Res. 2014, 4:128. 10.4103/2229- 516X.136806
Kamilos MF, Borrelli CL: New therapeutic option in genitourinary syndrome of menopause: pilot study using microablative fractional radiofrequency. Einstein (Sao Paulo. 2017, 15:445-51. 10.1590/S1679- 45082017AO4051
Scavello I, Maseroli E, Di Stasi V, Vignozzi L: Sexual health in menopause. Medicina (Kaunas. 2019, 55:.. 10.3390/medicina55090559
Alvisi S, Gava G, Orsili I, Giacomelli G, Baldassarre M, Seracchioli R, Meriggiola MC: Vaginal health in menopausal women. Medicina (Kaunas. 2019, 55:.. 10.3390/medicina55100615
Samuels JB, Garcia MA: Treatment to external labia and vaginal canal with CO2 laser for symptoms of vulvovaginal atrophy in postmenopausal women. Aesthet Surg J. 2019, 39:83-93. 10.1093/asj/sjy087
Eder SE: Early effect of fractional CO2 laser treatment in Post-menopausal women with vaginal atrophy. Laser Ther. 2018, 27:41-7. 10.5978/islsm.18- OR-04
Santoro N: Perimenopause: from research to practice. J Womens Health (Larchmt. 2016, 25:332-9. 10.1089/jwh.2015.5556
Ramsdell WM: Fractional carbon dioxide laser resurfacing. Semin Plast Surg. 2012, 26:125-30. 10.1055/s-0032-1329414
Palacios S: Ospemifene for vulvar and vaginal atrophy: an overview. Drugs Context. 2020, 9:.. 10.7573/dic.2020-3-2
Simon JA, Altomare C, Cort S, Jiang W, Pinkerton JV: Overall Safety of Ospemifene in Postmenopausal Women from Placebo-Controlled Phase 2 and 3 Trials. J Womens Health (Larchmt. 2018, 27:14-23. 10.1089/jwh.2017.6385
Wurz GT, Kao C-J, DeGregorio MW: Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause. Clin Interv Aging. 2014, 9:1939-50. 10.2147/CIA.S73753
Bruyniks N, Nappi RE, Castelo-Branco C, de Villiers TJ, Simon J: Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophy. Climacteric. 2016, 19:60-5. 10.3109/13697137.2015.1113517
Salcedo FL, Blanco ZE: Experience with ospemifene in patients with vulvovaginal atrophy treated with laser therapy: case studies. Drugs Context. 2020, 9:1-5. 10.7573/dic.2020-3-7
Preti M, Vieira-Baptista P, Digesu GA, et al.: The clinical role of LASER for vulvar and vaginal treatments in gynecology and female urology: an ICS/ISSVD best practice consensus document. J Low Genit Tract Dis. 2019, 23:151-60. 10.1097/LGT.0000000000000462